Correlation of serum iron levels with myocardial injury and pump failure in patients with acute ST-elevation myocardial infarction

Objective:To analyze the correlation of serum iron levels with myocardial injury and pump failure in patients with acute ST-elevation myocardial infarction. Methods:80 patients with acute ST-elevation myocardial infarction were divided into high iron group (serum iron≥8.95μmol/L) (n=43) and low iron group (serum iron<8.95μmol/L) (n=37) according to serum iron levels, differences in myocardial injury markers, ventricular remodeling indexes and pump failure-related indexes on admission were compared between two groups of patients, and the correlation of serum iron levels with myocardial damage and pump failure in patients with acute ST-elevation myocardial infarction was further analyzed. Results:Serum myocardial injury markers troponin I (cTnI), creatine kinase isoenzyme (CK-MB), myoglobin (Myo), ischemia modified albumin (IMA) and hydroxybutyrate dehydrogenase (HBDH) content of high iron group on admission were significantly lower than those of low iron group (P<0.05);left ventricular posterior wall thickness (LVPWT), left ventricular end-systolic interventricular septal thickness (IVST), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), end-systolic volume index (ESVI), end-diastolic volume index (EDVI), and the left ventricular mass index (LVMI) levels under color Doppler ultrasound were lower than those of low iron group (P<0.05);serum N-terminal pro-brain natriuretic peptide (NT-proBNP), galectin-3, adiponectin (APN), soluble P-selectin (sP-selectin) and Copeptin content were lower than those of low iron group (P<0.05). Pearson test showed that serum iron level was directly correlated with the degree of myocardial injury and pump failure in patients with acute ST-elevation myocardial infarction. Conclusions:Low serum iron levels is one of key factors causing severe cases and pump failure in STEMI patients, and early iron supplementation is expected to improve outcomes in STEMI patients with iron deficiency.

Effects of rh BNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure

Objective: To investigate the effects of exogenous recombinant human brain natriuretic peptide(rh BNP) after primary percutaneous coronary intervention(PCI) on non-invasive hemodynamic in acute myocardial infarction patients with left ventricular failure. Methods: A number of 96 acute myocardial infarction patients accompanied with heart failure after PCI hospitalized in the People's Hospital of Sanya during February 2012 to October 2015 were selected. They were randomly divided into the therapy group(n = 50) and control group(n = 46). On the basis of routine treatment, patients in the therapy group were treated with intravenous rh BNP(1.5 μg/kg was intravenous injection with uniform speed of 3 min, followed by continuous infusion 0.007 5 μg/kg·min for 72 h), while the control group received conventional treatment. Bio Z-2011 non-invasive hemodynamic real-time monitoring system was used to monitor the hemodynamic parameters changes and the leves of plasma pro-BNP, serum creatinine, serum potassium, serum sodium and urine volume of each group before and after treating for 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, 72 h. Results: Patients in the therapy group showed no effect on heart rate, while after 30 min of intravenous injection of rh BNP, CO, CI, SV, and SI increased significantly and LVET and TFC reduced at the same time, which had certain effect on blood pressure(SBP/DBP). Compared with the control group, the therapy group showed a faster and more effective improvement on haemodynamics. Conclusions: Acute myocardial infarction patients complicated with left heart failure after primary PCI can significantly improve hemodynamics by treating with rh BNP.

Clinical study of recombinant human brain natriuretic peptide in patients with acute myocardial infarction complicating congestive heart failure

Objectives To observe the efficacy and safety of recombinant human brain natriuretic peptide(rh-BNP) on patients with acute myocardial infarction complicating congestive heart failure.Methods 40 patients with acute myocardial infarction complicated by congestive heart failure were randomly divided into control group and treatment group of 20 cases.The control group,15 cases of acute anterior myocardial infarction,5 cases of acute inferior wall myocardial infarction, 15 males and 5 females,aged 55-70 years,mean age 58±12 years;treated 16 cases of acute anterior myocardial infarction,4 cases of acute myocardial infarction,16 males and 4 females,aged 56-70 years,mean age 59±11 years;two groups of age,gender,severity of disease and vascular lesions no significant difference and comparable(P】0.05).Conventional group were given aspirin,clopidogrel, statins,Inotropic,diuretic and vasodilator therapy.In the con- ventional treatment group based on the use of recombinant human brain natriuretic peptide(new bios,Tibet Pharmaceutical Co.,Ltd.Chengdu Nuodikang biopharmaceutical production, usage:1.5μg/Kg intravenous injection(impact), then 0.0075μg-0.01μg/(kg·min)infusion rate).Continuous medication 72 h.The clinical symptoms observed for 3 days in patients before treatment and after treatment,heart rate,blood pressure and left ventricular ejection fraction (LVEF) and tumor necrosis factor(TNF-α),brain natriuretic peptide(BNP) levels were measured.Results In control group,8 cases markedly effect,5 cases effect and 7 cases no effect,the total effective rate was 65%;In treatment group,13 cases markedly effect,6 cases effect and 1 cases no effect,the total effective rate was 95%,compared with two groups P New bios treatment group significantly increased cardiac index(CI) in patients with heart failure and left ventricular ejection fraction(LVEF) than the control group(all P【0.05),further reduce the levels of tumor necrosis (TNF-α) and brain natriuretic peptide(BNP).Conclusions rh-BNP can improve symptoms and heart function,reduced plasma tumor necrosis factor(TNF-α) and BNP levels of acute myocardial infarction patients with congestive heart failure,the treatment safe and reliable.As small sample size observed,larger sample to be accumulated to further evaluate its efficacy and safety.

Meta-analysis of the efficacy and safety of rhbnp in the treatment of acute myocardial infarction with heart failure

Objective:Systematic review of the efficacy and safety of neoactivin re-acute myocardial infarction with heart failure.Methods:The computer retrieved CNKI,Wan Fang,Weipu Chinese Science and Technology Periodicals Database(VIP),China Biomedical Literature Database(CBM),Medline,Cochrane Library,and Clinical Trail.Gov collected clinical randomized controlled trials(RCTs)of neoactivin in the treatment of acute myocardial infarction with heart failure from the establishment of the database to December 2019.Data were extracted according to the Jadad scale,disease inclusion and exclusion criteria,and RevMan 5.3 software was used for Meta analysis.Results:A total of 23 RCTs were included,with a total of 2024 patients,including 1012 patients in the control group(conventional treatment with western medicine)and 1012 patients in the test group(on the basis of the control group+neoactivin treatment).Meta analysis results show that:in the total effective rate,the test group was better than the control group,and the difference was statistically significant(OR=4.30,95%CI[3.26,5.67],P<0.00001);In terms of left ventricular ejection fraction,the test group was better than the control group,and the difference was statistically significant(OR=1.58,95%CI[1.27,1.90],P<0.00001).In terms of the left ventricular end-diastolic diameter,the test group was better than the control group,with a statistical difference Significance(OR=-0.91,95%CI[-1.50,-0.33],P=0.002);In terms of stroke volume,the test group was better than the control group,and the difference was statistically significant(OR=1.24,95%CI[0.55,1.94],P=0.0005);In terms of brain natriuretic peptide precursors,the experimental group was better than the control group,the difference was statistically significant(OR=-4.37,95%CI[-6.21,-3.25],P<0.00001);In terms of heart rate,the test group was better than the control group,and the difference was statistically significant(OR=-13.70,95%CI[-14.95,-12.46],P<0.00001);In terms of systolic blood pressure,the test group was better than the control Group,the difference was statistically significant(OR=-12.38,95%CI[-17.98,-6.79],P<0.00001);In diastolic blood pressure,the test group was better than the control group Group,the difference was statistically significant(OR=-7.42,95%CI[-8.53,-6.30],P<0.00001);In terms of adverse reactions,the difference was not statistically significant(OR=0.95,95%CI[0.29,3.16],P=0.94).Conclusions:In patients with acute myocardial infarction and heart failure,the timely application of neoactivin treatment can improve clinical efficacy,improve cardiac function,inhibit ventricular remodeling,improve blood pressure and heart rate,which has good clinical efficacy and safety.

Effect of recombinant human brain natriuretic peptide on serum inflammatory factors, neuroendocrine hormones and cardiac function in patients with acute myocardial infarction complicated with heart failure

Objective:To investigate the effect of recombinant human brain natriuretic peptide (BNP) on inflammatory factors, neuroendocrine hormones and cardiac function indexes in patients with acute myocardial infarction complicated with heart failure.Methods:A total of91 cases of acute myocardial infarction with heart failure patients were divided into the control group (n=44) and observation group (n=47) according to the random data table, two groups of patients were given conventional treatment, based on this, the control group was given intravenous infusion of Nitroglycerin Injection treatment, the observation group received intravenous injection of recombinant human brain natriuretic peptide treatment, compared serum inflammatory factors, neuroendocrine hormone and cardiac function and other indexes of two groups before and after treatment.Results: there was no significant difference between the two groups before treatment. After treatment, the levels of TNF-α, hs-CRP, IL-6, MCP-1, LVESD and LVEDD in the two groups were significantly lower than those within the group before treatment, and the observation group was significantly lower than the control group;The two groups after treatment LVEF levels were significantly higher than those in the group before treatment, and the observation group was significantly higher than that of control group;the observation group after treatment PRA, Ang II and ALD and NE levels were significantly lower than those before treatment, and was significantly lower than the control group after treatment, the difference was significant, PRA, Ang, ALD and NE levels of control group before and after the treatment was no significant difference.Conclusion:recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction with heart failure can effectively reduce the serum inflammatory factors and neuroendocrine hormone levels, improve heart function, and have a certain clinical value.

Effect of Guanxin-V Mixture Combined with Sacubitril Valsartan on Cardiac Function after PCI in STEMI Patients

[Objectives]To observe the effect of Guanxin-V Mixture combined with Sacubitril Valsartan on cardiac function in patients after PCI for acute ST-segment elevation myocardial infarction(STE-MI).[Methods]41 cases of STEMI patients(qi and yin deficiency and blood stasis and obstruction)hospitalized in Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine from January 2020 to June 2021 were randomly divided into 21 cases in the treatment group and 20 cases in the control group,and the two groups were given standardized Western medicine treatment as soon as possible after PCI.The control group was treated with Sacubitril Valsartan,and the treatment group was treated with Guanxin-V Mixture on the basis of treatment in the control group.The patients in the two groups were treated for 3 months,and the TCM syndrome score,left ventricular ejection fraction(LVEF),and N-Terminal Pro-Brain Natriuretic Peptide(NT-proBNP),interleukin-6(IL-6),and high-sensitivity C-reactive protein(hs-CRP)levels,and the incidence of heart failure and adverse reactions in the two groups after treatment were recorded.[Results]After the treatment,the TCM syndrome score and serum NT-proBNP,IL-6 and hs-CRP levels of the two groups significantly decreased(P<0.05),and the levels of the treatment group were significantly lower than those of the control group(P<0.05);the LVEF of the two groups significantly increased(P<0.05),and the level of the treatment group was significantly higher than that of the control group(P<0.05).Comparison of the incidence of heart failure and adverse reactions in the two groups showed no statistically significant differences(P>0.05).[Conclusions]Guanxin-V Mixture combined with Sacubitril Valsartan could significantly improve cardiac function in STEMI patients undergoing PCI,and its effect may be related to the suppression of inflammatory response.

Acute myocardial infarction induced by eosinophilic granulomatosis with polyangiitis:A case report

BACKGROUND Eosinophilic granulomatosis with polyangiitis(EGPA)is a multisystem disease characterized by allergic rhinitis,asthma,and a significantly high eosinophil count in the peripheral blood.It mainly involves the arterioles and venules.When the coronary arteries are invaded,it can lead to acute myocardial infarction(AMI),acute heart failure,and other manifestations that often lead to death in the absence of timely treatment.CASE SUMMARY A 69-year-old man was admitted to the emergency department due to chest pain for more than 1 h.He had a past history of bronchial asthma and chronic obstructive pulmonary disease and was diagnosed with AMI and heart failure.Thrombus aspiration of the left circumflex artery and percutaneous transluminal coronary angioplasty were performed immediately.After surgery,the patient was admitted to the intensive care unit.The patient developed eosinophilia,and medical history taking revealed fatigue of both thighs 1 mo prior.Local skin numbness and manifestations of peripheral nerve involvement were found on the lateral side of the right thigh.Skin biopsy of the lower limbs pathologically confirmed EGPA.The patient was treated with methylprednisolone combined with intravenous immunoglobulin and was discharged after 21 d.On follow-up at 7 d after discharge,heart failure recurred.The condition improved after cardiotonic and diuretic treatment,and the patient was discharged.CONCLUSION Asthma,impaired cardiac function,and eosinophilia are indicative of EGPA.Delayed diagnosis often leads to heart involvement and death.

Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes

BACKGROUND Coronary heart disease and type 2 diabetes mellitus(T2DM)frequently coexist,creating a complex and challenging clinical scenario,particularly when complicated with acute myocardial infarction(AMI).AIM To examine the effects of dapagliflozin combined with sakubactrovalsartan sodium tablets on myocardial microperfusion.METHODS In total,98 patients were categorized into control(n=47)and observation(n=51)groups.The control group received noxital,while the observation group was treated with dapagliflozin combined with noxital for 6 months.Changes in myocardial microperfusion,blood glucose level,cardiac function,N-terminal prohormone of brain natriuretic peptide(NT-proBNP)level,growth differentiation factor-15(GDF-15)level,and other related factors were compared between the two groups.Additionally,the incidence of major adverse cardiovascular events(MACE)and adverse reactions were calculated.RESULTS After treatment,in the observation and control groups,the corrected thrombolysis in myocardial infarction frame counts were 37.12±5.02 and 48.23±4.66,respectively.The NT-proBNP levels were 1502.65±255.87 and 2015.23±286.31 pg/mL,the N-terminal pro-atrial natriuretic peptide(NT-proANP)levels were 1415.69±213.05 and 1875.52±241.02 ng/mL,the GDF-15 levels were 0.87±0.43 and 1.21±0.56 g/L,and the high-sensitivity C-reactive protein(hs-CRP)levels were 6.54±1.56 and 8.77±1.94 mg/L,respectively,with statistically significant differences(P<0.05).The cumulative incidence of MACEs in the observation group was significantly lower than that in the control group(P<0.05).The incidence of adverse reactions was 13.73%(7/51)in the observation group and 10.64%(5/47)in the control group,with no statistically significant difference(P>0.05).CONCLUSION Dapagliflozin combined with nocinto can improve myocardial microperfusion and left ventricular remodeling and reduce MACE incidence in patients with post-AMI heart failure and T2DM.The underlying mechanism may be related to the reduction in the expression levels of NT-proANP,GDF-15,and hs-CRP.

Clinical study of impedance cardiography combined with passive leg raise test for non-invasive hemodynamic monitoring and treatment in patients with acute myocardial infarction complicated with heart failure

Background Active and effective treatment of acute myocardial infarction(AMI)with heart failure will significantly improve the patient’s prognosis and quality of life.The selection of clinical heart failure drugs is guided by the comprehensive judgment of central venous pressure,chest X-ray lung congestion degree,serum B-type natriuretic peptide(BNP)value,echocardiogram,blood pressure,etc.,which is currently the most commonly used method in clinical practice.However,the prolonged results of chest X-ray,serum BNP value and echocardiogram affect the real-time judgment of hemodynamics,which affect the accuracy of drug selection for patients with heart failure.The impedance cardiography(ICG)for hemodynamic monitoring technology can supply immediately hemodynamic results,which has been used less for the patients of AMI with heart failure at home and abroad.Therefore,this study was to evaluate the application value of ICG combined with the passive leg raise test(PLR)in AMI patients with heart failure.Methods 110 patients with AMI combined with killip grade 2 and above were randomly divided into a control group(n=55)and an ICG group(n=55).In the ICG group,heart failure treatment drugs were selected according to some parameters measured by ICG.In the control group,the treatment drugs for heart failure were selected according to routine symptoms,signs,BNP,etc.The associations of some ICG parameters of all patients with BNP,left ventricular ejection fraction(LVEF)values were analyzed.The value of BNP,LVEF value and the 6-minute walking distance(6 MWD)were determined between the two groups,on the 7th day after surgery.Results BNP value was negatively correlated with cardiac output(CO),cardiac output index(CI),stroke volume(SV),stroke output index(SI),left ventricular stroke work(LSW),left ventricular stroke work index(LSWI),left ventricular ejection time(LVET),ejection period contraction index(EPCI)(P<0.05)and positively correlated with stroke system vascular resistance(SSVR)/index(SSVRI),system volume resistance(SVR),pre-ejection period(PEP),shrink time ratio(STR)(P<0.05).Moreover,LVEF value was positively correlated with CO,CI,SV,SI,heart rate rhythm,LSW,LSWI,LVET,EPCI(P<0.05),and negatively correlated with SSVR,SSVRI,SVR,vascular elasticity,PEP,STR(P<0.05).On the 7 thpostoperative day,the BNP levels were decreased in the both two groups,and the BNP values were decreased more significantly in the ICG group compared to the control group(P<0.05).Moreover,the 6 MWD in the ICG group were significantly increased compared to the control group(P<0.05).Conclusions Some ICG parameters can reflect the early cardiac function of patients with AMI and heart failure after PCI treatment.By using ICG technology,the patient’s hemodynamics and cardiac function can be more accurately judged,and the drugs for heart failure can be further adjusted to promote the patient’s early recovery and improve the quality of life.

血清成纤维细胞生长因子21和脂肪酸结合蛋白4检测对急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后心力衰竭的预测价值

目的探究血清成纤维细胞生长因子21(FGF21)和脂肪酸结合蛋白4(FABP4)检测对急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)术后心力衰竭的预测价值。方法选取2020年9月至2022年9月内蒙古医科大学附属医院接诊的113例STEMI患者为研究对象,依据PCI术后1年是否发生心力衰竭(心衰),将其分为心衰组(n=32)和非心衰组(n=81)。应用ELISA法测定血清FGF21、FABP4表达水平,比较两组血清FGF21、FABP4水平,多因素logistic回归分析影响STEMI患者PCI术后发生心力衰竭的相关因素,ROC曲线评估血清FGF21、FABP4水平对STEMI患者PCI术后心力衰竭发生的预测价值。结果心衰组心率次数、C反应蛋白(CRP)、心肌肌钙蛋白(cTnI)、N末端B型利钠肽原(BNP)、利尿剂使用比例均显著高于非心衰组,左心室射血分数(LVEF)显著低于非心衰组(P<0.05)。心衰组血清FGF21、FABP4表达水平均明显高于非心衰组[(228.37±33.07)ng/L比(185.68±25.52)ng/L、(34.26±5.51)ng/ml比(26.87±4.67)ng/ml,t=7.345、7.195,P<0.05]。血清FGF21(95%CI 1.371~8.191)、FABP4(95%CI 1.176~4.090)及发病到至导丝通过时间(95%CI 1.058~8.157)是影响STEMI患者PCI术后发生心力衰竭的危险因素(OR>1,P<0.05),LVEF(95%CI 0.473~0.913)是保护因素(OR<1,P<0.05)。血清FGF21、FABP4单独及二者联合预测STEMI患者PCI术后发生心力衰竭的曲线下面积(AUC)分别为0.828、0.856、0.934,二者联合优于单一(Z二者联合-FGF21=1.971、Z二者联合-FABP4=2.417,P=0.048、P=0.015)。结论STEMI患者PCI术后发生心力衰竭血清FGF21、FABP4水平均明显升高,二者联合对STEMI患者PCI术后发生心力衰竭的风险具有更高的预测价值。

急性心肌梗死合并心原性休克患者器械辅助支持下直接经皮冠状动脉介入治疗预后不良的因素分析

目的本研究旨在考察急性心肌梗死合并心原性休克患者直接经皮冠状动脉介入治疗(PPCI)术后预后不良的影响因素。方法入选2015年1月至2019年12月期间,河南中医药大学第一附属医院胸痛中心收治急性心肌梗死合并心原性休克并且行PPCI的患者,收集其临床基线特征、冠状动脉造影及PPCI相关参数、器械辅助支持信息等。根据1年内随访生存与否,分为生存组与死亡组,比较两组各项因素。结果共入选40例患者,其中生存组26例,死亡组14例。两组在基线资料、入院诊断、危险因素及合并症等方面差异均无统计学意义(均P>0.05);生存组较死亡组有入院时心率较低、血压较高的趋势;生存组心肌酶显著低于死亡组(肌酸激酶峰值:496.00(198.25,2830.00)U/L比3040.00(405.75,5626.53)U/L,P=0.003;肌酸激酶同工酶MB型峰值:52.65(31.75,219.50)U/L比306.00(27.25,489.63)U/L,P=0.006);两组间在冠状动脉造影及PPCI相关指标方面比较,生存组较对照组有更高的完全血运重建率(53.85%比21.43%,P=0.048);两组器械辅助支持方面比较,生存组较死亡组有更多的体外膜肺氧合(ECMO)联合主动脉内球囊反搏(IABP)支持的比例(38.46%比7.14%,P=0.034)。结论急性心肌梗死合并心原性休克行PPCI的患者的预后与心肌酶水平、ECMO联合IABP支持以及完全血运重建有关。

新型口服抗凝药对急性心肌梗死后心力衰竭合并室壁瘤附壁血栓消退影响的研究

目的:探讨新型口服抗凝药(novel oral anticoagulants,NOAC)用于治疗急性心肌梗死(acute myocardial infarction,AMI)后心力衰竭合并室壁瘤内附壁血栓的疗效。方法:入选2019年6月至2023年5月,首都医科大学附属北京安贞医院心内科门诊和病房患者中AMI后发生心力衰竭合并室壁瘤内附壁血栓患者118例,分别给予NOAC(NOAC组,65例)或维生素K受体拮抗剂(VKA组,53例)治疗,3个月后复查经胸超声心动图,如血栓尚未完全溶解,则在首次给药6个月后再次复查超声心动图。结果:NOAC组中,使用利伐沙班治疗者为46例,使用达比加群治疗者为19例,治疗3个月后血栓完全溶解率为70.8%。所有VKA组患者均使用华法林治疗,3个月后血栓完全溶解率为67.9%,与NOAC组相比差异无统计学意义(P>0.05)。治疗6个月后,NOAC组的血栓完全溶解率为90.8%,VKA组的血栓完全溶解率为84.9%,两组血栓溶解率对比差异无统计学意义(P>0.05)。结论:NOAC可考虑作为AMI后心力衰竭合并室壁瘤内附壁血栓消退的治疗药物,且无须监测INR,使用方便,安全性好。

血清Sulfatide、ANGPTL4在急性心肌梗死合并心力衰竭中的表达

目的分析血清硫苷脂(Sulfatide)、血管生成素样蛋白4(ANGPTL4)在急性心肌梗死合并心力衰竭中的表达情况。方法收集2021年6月至2022年4月于郑州大学第二附属医院心内科治疗的70例急性心肌梗死合并心力衰竭患者(AMI-HF组)和87例急性心肌梗死未合并心力衰竭的患者(AMI组)外周血,采用酶联免疫法(ELISA)检测两组血清Sulfatide和ANGPTL4水平;采用Logistic回归分析AMI患者发生心力衰竭的影响因素,采用Pearson分析血清Sulfatide和ANGPTL4水平与AMI-HF患者心功能指标的相关性,分析血清Sulfatide和ANGPTL4水平在评估AMI-HF疾病进展的应用价值。结果两组年龄、性别、心率、高血压、糖尿病、吸烟史比较,差异无统计学意义(P>0.05);AMI-HF组Sulfatide、LVEDVI、LVESVI均显著高于AMI组,ANGPTL4、LVEF低于AMI组,差异有统计学意义(P<0.05);Logistic回归分析发现,Sulfatide、ANGPTL4、LVEF、LVEDVI、LVESVI是AMI患者发生心力衰竭的影响因素(P<0.05);相关性分析结果显示,AMI-HF患者血清Sulfatide与LVEF呈显著负相关(P<0.05),与LVEDVI、LVESVI呈正相关(P<0.05);ANGPTL4与LVEF呈显著正相关(P<0.05),与LVEDVI、LVESVI呈负相关(P<0.05);AMI-HF患者中,预后良好组患者血清Sulfatide均显著低于预后不良组,ANGPTL4高于预后不良组,差异有统计学意义(P<0.05);血清Sulfatide和ANGPTL4联合预测AMI-HF预后价值高于单独检测(P<0.05)。结论监测AMI-HF患者血清Sulfatide和ANGPTL4水平可为疾病进展提供客观依据,血清Sulfatide和ANGPTL4二者还可为作为预测AMI-HF患者预后的重要指标。

左西孟旦在急性心肌梗死合并心力衰竭患者中的应用

目的 分析左西孟旦在急性心肌梗死(AMI)合并心力衰竭患者中的应用效果。方法 选取2018年1月至2022年11月北京市大兴区人民医院收治的106例AMI合并心力衰竭患者作为研究对象,按照随机数字表法将其分为两组,各53例。对照组采用标准化治疗,观察组同时联合左西孟旦治疗。比较两组治疗前后血清炎症因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]、血流动力学水平[心指数(CI)、全心舒张末容积指数(GEDVI)、全身血管阻力指数(SVRI)]、心功能指标[左室射血分数(LVEF)、每搏输出量(SV)、B型尿钠肽(BNP)],及临床疗效和不良反应总发生率。结果 治疗后,两组hs-CRP、IL-6、TNF-α、GEDI、SVRI、BNP水平均低于治疗前,且观察组低于对照组(P<0.05);治疗后,两组CI、LVEF、SV水平均高于治疗前,且观察组高于对照组(P<0.05)。观察组临床疗效高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 标准化治疗基础上联合左西孟旦治疗AMI合并心力衰竭能够有效缓解患者的炎症反应,稳定血流动力学,改善心功能和临床疗效,且无明显不良反应。

急性心肌梗死合并急性左心衰患者血清铁调素/铁蛋白比值与临床救治效果的关系

目的 探讨急性心肌梗死合并急性左心衰竭(简称急性左心衰)患者血清铁调素/铁蛋白比值与临床救治效果的关系。方法 将绵阳市中心医院2020年1月至2023年5月收治的303例急性心肌梗死合并急性左心衰患者作为研究对象,根据其治疗1周的临床救治效果分为有效组与无效组,观察两组入院时、治疗1周时血清铁调素、铁蛋白及其比值变化情况,统计并比较两组一般资料及其他实验室指标包括血红蛋白、高敏肌钙蛋白、N端脑利钠肽前体等,通过点二列相关性分析入院时血清铁调素、铁蛋白及其比值与患者临床救治效果的关系,并通过受试者工作特征(ROC)曲线评价入院时血清铁调素、铁蛋白及其比值预测患者救治效果的价值;同时选取2023年5月至2023年10月医院收治的另外68例急性心肌梗死合并急性左心衰患者作为验证对象,通过ROC曲线进一步验证血清铁调素/铁蛋白比值对患者救治效果的预测价值。结果 本研究根据纳入、排除标准共选取308例患者为研究对象,最终303例患者完成救治效果评价,其中有效257例(84.82%)。与有效组比较,无效组入院时、治疗1周时血清铁调素及其与铁蛋白比值均较高,血清铁蛋白水平较低(P<0.05)。与入院时比较,有效组治疗1周时血清铁调素及其与铁蛋白比值均降低,血清铁蛋白水平均升高(P<0.05),但无效组入院时、治疗1周时血清铁调素、铁蛋白及其比值差异无统计学意义(P>0.05)。两组入院时高敏肌钙蛋白、N端脑利钠肽前体、血红蛋白水平比较差异有统计学意义(P<0.05)。点二列相关性发现,患者临床救治效果与入院时血清铁调素水平及其与铁蛋白比值呈正相关(r>0,P<0.05),与入院时血清铁蛋白水平呈负相关(r<0,P<0.05)。ROC曲线发现,入院时血清铁调素、铁蛋白及其比值对患者救治效果均有一定预测价值,且二者比值预测价值更高。加以验证的ROC曲线结果显示,入院时血清铁调素/铁蛋白比值对患者救治效果仍有良好的预测价值。结论 急性心肌梗死合并急性左心衰患者入院时血清铁调素/铁蛋白比值与临床救治效果有关,可辅助临床早期预测患者救治效果,指导救治方案的及时调整。

中药黄芪的药理作用分析及临床应用效果

目的分析中药黄芪的药理作用及其临床应用效果。方法选取2022年10月—2023年10月青岛大学附属泰安市中心医院采用黄芪治疗的88例患者作为观察组,另选择同期应用西医治疗的88例作为对照组,观察运用中药黄芪后患者的临床疗效。结果观察组(95.45%)急性心肌梗死合并心力衰竭总有效率高于对照组(72.73%)(P<0.05)。观察组(90.91%)扩张型心肌病伴心力衰竭总有效率高于对照组(68.18%)(P<0.05)。观察组糖尿病周围神经病变总有效率(100%)高于对照组(77.27%)(P<0.05)。观察组脑血栓总有效率(95.45%)高于对照组(68.18%)(P<0.05)。结论中药黄芪在治疗糖尿病周围神经病变、急性心肌梗死伴心衰、脑血栓后遗症以及扩张型心肌病合并心力衰竭患者中疗效较理想,为临床治疗提供有力依据,同时也为中药在心血管和神经系统疾病治疗中的应用提供新思路。但仍需要进一步的研究来验证其机制和安全性。

Circulating MicroRNA-145 is Associated with Acute Myocardial Infarction and Heart Failure

Background： Recent studies show that microRNA- 145 （miRNA- 145 ） might be an attractive tumor biomarker of considerable prognostic value, but little is known about their relationship with acute myocardial infarction （AMI）. This study investigated the correlation between the level of miR-145 and AM1. Methods： One-hundred patients were divided into three groups： no coronary artery disease （CAD） group, non-ST segment elevation myocardial infarction group, and ST segment elevation myocardial infarction group. The plasma levels of miR-145 were quantified using real-time quantitative polymerase chain reaction. Logarithmic transformation of miRNA-145 levels （Ln_rniRNA-145） was used for statistical analysis due to the skewed data distribution. Results： Plasma levels of miR-145 were significantly lower in patients with AMI compared to patients in the non-CAD group （-6.38 ± 0.11 vs. -4.47 ＋ 0.17, P 〈 0.0001）. Compared to those without heart failure, the levels of miR-145 were significantly lower in patients with heart failure （-6.91 ± 0.20 vs. -5.35 ± 0.13, P 〈 0.0001）. We also found that the lower plasma levels of miRNA-145 significantly correlated with increased serum levels of B-type natriuretic peptide （Spearman ρ = -0.60, P 〈 0.0001）, troponin T （Spearman p = -0.62, P 〈 0.0001）, and decreased ejection fraction （Spearman ρ = 0.65, P 〈 0.0001）. In a multivariable linear regression analysis, AMI and heart failure were independently associated with lower Ln miRNA-145 （estimate -0.99, standard error [SE] 0.28; P = 0.001 and estimate -0.62, SE 0.21 ; P = 0.004）. Conclusions： Our results suggest that decreased plasma levels of miR-145 are associated with AMI. Circulating miR-145 may be useful in prognosticating cardiac function and the risk of developing heart failure.

巴中市80例急性ST段抬高型心肌梗死患者发生心力衰竭的危险因素分析

目的 分析巴中市急性ST段抬高型心肌梗死(STEMI)患者发生心力衰竭(HF)的现状及其影响因素。方法 选取2021年1月1日—2023年4月30日巴中市中心医院80例STEMI患者,根据有无发生HF分组,探寻可能导致STEMI患者HF的危险因素。结果 入组患者中28例发生HF,发生率35.00%。有HF组血清降钙素原(PCT)、总胆红素(TBiL)、超敏C反应蛋白(hs-CRP)、血小板平均体积(MPV)、同型半胱氨酸(Hcy)表达均较无HF组高(t=13.176、10.485、32.544、10.113、4.254,P<0.05);组间其他资料比较无统计学差异(P>0.05);Logistic回归分析显示血清PCT、TBiL、hs-CRP、MPV、Hcy高表达是导致STEMI患者发生HF的危险因素(OR>1,P<0.05)。结论 STEMI患者发生HF与血清PCT、TBiL、hs-CRP、MPV、Hcy指标高表达相关。

双心护理对急性心肌梗死患者IABP术后负性情绪及舒适度的影响观察

目的:探讨双心护理应用于急性心肌梗死患者主动脉球囊反搏泵(IABP)术后负性情绪及舒适度的影响观察。方法:选取2019年1月—2021年12月河南科技大学第一附属医院收治的72例急性心肌梗死IABP术后患者作为研究对象,随机分为常规组36例实施常规护理、观察组36例在常规护理基础上另给予双心护理,两组患者均持续治疗3个月后评价效果。采用医院焦虑抑郁量表(PANAS)评估患者焦虑抑郁情绪,比较患者舒适度(Kolcaba舒适量表评分)及并发症发生情况。结果:护理后,两组患者舒适度评分均升高,且观察组患者生理、心理精神、社会文化和环境评分均高于常规组,差异有统计学意义(t=12.099、6.118、2.864、2.278,P<0.05);护理后,两组患者PANAS评分较术前降低,且观察组患者PANAS评分低于常规组,差异有统计学意义(t=16.535,P<0.05);两组患者并发症发生情况比较,观察组患者并发症发生率明显低于常规组,差异有统计学意义(χ^(2)=3.863,P<0.05)。结论:对急性心肌梗死患者IABP术后采用双心护理,能够明显改善患者的舒适度和负性情绪,降低并发症发生率。